Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity
US8785488B2 · kind B2 · utility
2Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2010 |
| Grant date | Jul 22, 2014 |
| Priority date | — |
| Expiry date | Sep 25, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises TGR5 agonists of structural formula I,wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.